Trial | NCT03196921  Report issue

Title

Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
A Prospective Cohort to Evaluate the Efficacy and Safety of Oral Encochleated Amphotericin B (CAMB/MAT2203) for the Treatment of Cryptococcal Infection

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Withdrawn

  • Study Participants

    0
This will be an open label phase I/II prospective cohort study to determine the efficacy and safety of CAMB for the treatment and prevention of cryptococcal infection.
Study Started
Oct 01
2018
Anticipated
Primary Completion
Oct 01
2019
Anticipated
Study Completion
Mar 01
2020
Anticipated
Last Update
Mar 08
2019

Drug Encochleated Amphotericin B

lipid-crystal nanoparticle formulation of amphotericin B; oral

  • Other names: CAMB, MAT2203

Symptomatic Cryptococcal Meningitis Experimental

CAMB (Encochleated Amphotericin B)

Asymptomatic Cryptococcal Antigenemia Experimental

CAMB (Encochleated Amphotericin B)

Criteria 

Inclusion Criteria:

HIV infection, informed consent, cryptococcal infection present, diagnosed by either: CSF cryptococcal culture, CSF cryptococcal antigen (CRAG), plasma/serum CRAG

Exclusion Criteria:

Presence of jaundice or known liver cirrhosis, >72 hours antifungal therapy, pregnancy or breastfeeding, unlikely to attend regular clinic visits
No Results Posted